What are the recommended dosing, monitoring, efficacy, and safety data for pexidartinib in patients with symptomatic, unresectable or recurrent diffuse pigmented villonodular synovitis of the knee?

Pexidartinib for Tenosynovial Giant Cell Tumor (TGCT)

Pexidartinib is the only FDA-approved systemic therapy for symptomatic, unresectable or recurrent diffuse-type TGCT (pigmented villonodular synovitis), demonstrating a 39% response rate at 25 weeks and sustained clinical benefit with long-term treatment, though it carries a significant risk of mixed or cholestatic hepatotoxicity requiring mandatory monitoring. 1, 2

Indications and Patient Selection

Pexidartinib should be reserved for adult patients with symptomatic TGCT associated with severe morbidity or functional limitations who are not amenable to improvement with surgery 3, 4. The 2025 UK guidelines specifically recommend pexidartinib (along with imatinib and nilotinib) for symptomatic diffuse disease to improve symptoms and function 3. The 2022 SELNET guidelines similarly endorse pexidartinib for unresectable, symptomatic patients 4.

Key selection criteria:

• Diffuse-type TGCT with significant functional impairment
• Surgery not recommended due to anatomic location, high surgical morbidity risk, or recurrent disease after multiple surgeries
• Adequate baseline liver function (critical given hepatotoxicity risk)
• Ability to comply with mandatory monthly liver function monitoring

Dosing Regimen

Standard dosing:

• Loading dose: 1000 mg/day orally (400 mg morning, 600 mg evening) for the first 2 weeks
• Maintenance dose: 800 mg/day (400 mg twice daily) thereafter 1, 2

Alternative low-fat meal dosing:

• 250 mg twice daily with a low-fat meal achieves bioequivalent exposure to 400 mg fasted twice daily
• This regimen may improve compliance for long-term treatment 5

Dose modifications:

• In real-world practice, 35% of patients required dose reduction from initial dosing, typically due to adverse events 6
• Most responders achieved benefit at the 800 mg dose level rather than reduced doses 2

Efficacy Data

Primary Response Outcomes

The pivotal ENLIVEN trial (phase 3, randomized, placebo-controlled) demonstrated:

• RECIST v1.1 overall response rate (ORR) at week 25: 39% (24/61) vs 0% (0/59) for placebo (p<0.0001) 1
• Tumor volume score (TVS) ORR at week 25: Higher sensitivity than RECIST for TGCT assessment 1

Long-Term Efficacy

With median follow-up of 31.2 months in the final ENLIVEN analysis 2:

• RECIST ORR: 60.4% (increased from 39% at week 25)
• TVS ORR: 68.1%
• Median duration of response: Not reached (range 0.03-63.4 months)
• Progressive disease rate: Only 3% (3/91) of patients progressed without dose reduction/interruption
• Most responses occurred within the first 6 months of treatment

Functional Outcomes

Range of motion improvement:

• Mean change at week 25: +23.05 degrees 7
• Improvement noted as early as week 13 (+15.64 degrees) 7

Patient-reported outcomes:

• 78.3% reported overall TGCT symptom improvement 6
• 77.2% reported physical function improvement 6
• Worst stiffness NRS: decreased from 6.2 to 3.0 (p<0.05) 6
• Worst pain NRS: decreased from 5.7 to 2.7 (p<0.05) 6
• PROMIS-PF and EQ-5D-5L scores improved or maintained throughout treatment 2, 8

East Asian Population Data

A phase 3 study in 40 East Asian patients demonstrated comparable efficacy 7:

• RECIST v1.1 ORR: 22.5% at week 25
• TVS ORR: 47.5% at week 25
• Best overall response by RECIST: 30.0%
• Safety profile consistent with global studies

Monitoring Requirements

Hepatotoxicity Surveillance (Critical)

Pexidartinib carries a boxed warning for serious and potentially fatal hepatotoxicity, including mixed or cholestatic liver injury. This requires enrollment in a Risk Evaluation and Mitigation Strategy (REMS) program.

Mandatory monitoring schedule:

• Baseline: Complete liver function tests (ALT, AST, total bilirubin, alkaline phosphatase) before initiating therapy
• During treatment: Monthly liver function tests for the first 6 months, then every 3 months thereafter
• After discontinuation: Continue monthly monitoring for at least 3 months

Management of liver enzyme elevations:

• ALT or AST ≥3× ULN: Occurred in 31% of patients 2
• ALT or AST ≥5× ULN: Occurred in 19% of patients 2
• Mixed or cholestatic hepatotoxicity (ALT/AST ≥3× ULN with total bilirubin ≥2× ULN and alkaline phosphatase ≥2× ULN): Occurred in 3 patients in ENLIVEN, with one case lasting 7 months and confirmed by biopsy 1

Action required: Immediately discontinue pexidartinib if mixed or cholestatic hepatotoxicity develops. Do not restart.

Other Monitoring

• Baseline and periodic: Complete blood count, renal function
• Clinical assessment: Every 3 months for tumor response (imaging), symptoms, and functional status
• Imaging: MRI or CT every 3 months to assess response by RECIST v1.1 and TVS

Safety Profile

Most Common Adverse Events (Any Grade)

From the ENLIVEN trial and long-term follow-up 1, 2:

• Hair color changes: 67-77.5% (typically hypopigmentation, mild, reversible)
• Fatigue: 54%
• AST increase: 39-57.5%
• Nausea: 38%
• ALT increase: 28-60%
• Dysgeusia: 25%
• Pruritus: 47.5%
• Blood lactate dehydrogenase increase: 47.5%

Grade ≥3 Treatment-Emergent Adverse Events

• AST increase: 9%
• ALT increase: 10%
• Hypertension: 8%
• Serious adverse events: 13% (vs 2% for placebo) 1

Important Safety Considerations

No new safety signals emerged with long-term treatment (median 31.2 months follow-up) 2. The safety profile in East Asian patients was comparable to global studies 7.

Contraindications:

• Pre-existing hepatic impairment or active liver disease
• Pregnancy and breastfeeding (not studied)
• Inability to comply with monthly liver monitoring

Treatment Duration and Discontinuation

Optimal Duration

Continue pexidartinib until disease progression, unacceptable toxicity, or achievement of maximal clinical benefit. In the ENLIVEN study, median time on treatment was 6 months at the time of the patient survey 6, but long-term data show sustained benefit beyond 5 years in some patients 2.

Discontinuation Outcomes

A phase 4 study evaluated outcomes after stopping pexidartinib 8:

• 54.5% of patients who discontinued developed progressive disease during the treatment-free period
• Median progression-free survival after stopping: 22.8 months
• Probability of remaining treatment-free at 24 months: 73%
• Patients who continued pexidartinib: 0% progression rate

Retreatment After Discontinuation

Three patients who stopped and then restarted pexidartinib 8:

• All achieved disease stabilization within 6 months of retreatment
• Two patients had clinically significant improvements in physical function scores
• No new safety concerns with retreatment
• Retreatment is safe and effective if disease progresses after discontinuation

Comparison with Alternative Therapies

Surgery

The 2025 UK guidelines note that surgery for diffuse-type TGCT has high local recurrence rates and may result in loss of function 3. Pexidartinib offers a non-surgical option that avoids surgical morbidity while achieving tumor response and functional improvement.

Other Systemic Agents

The 2018 ESMO-EURACAN guidelines mention imatinib and nilotinib as options for TGCT, noting they can induce tumor stabilization or shrinkage 9. However, pexidartinib is the only agent with level II, B evidence from a randomized controlled trial 4. The 2025 UK guidelines note pexidartinib is the only licensed treatment (in the USA) 3.

Radiotherapy

Radiotherapy is not considered standard treatment for TGCT due to concerns about late radiation toxicity and radiation-induced malignancy in this young patient population 3. It may have a role in very selected patients where systemic therapy is not an option.

Clinical Pearls and Pitfalls

Common pitfalls to avoid:

1. Failing to enroll patients in the REMS program before prescribing – This is mandatory and includes patient education about hepatotoxicity risk
2. Inadequate liver monitoring – Monthly monitoring is non-negotiable for the first 6 months
3. Continuing treatment despite hepatotoxicity warning signs – Mixed or cholestatic pattern requires immediate discontinuation
4. Premature discontinuation in responding patients – Most responses occur within 6 months, but benefit continues long-term
5. Using pexidartinib in patients with resectable disease – Surgery remains first-line when feasible without significant morbidity

Optimizing outcomes:

• Consider the low-fat meal dosing regimen (250 mg BID with food) to improve long-term compliance 5
• Assess functional outcomes (ROM, pain, stiffness) in addition to radiographic response, as patient-reported benefits are substantial 6
• For patients with dose-limiting toxicity, recognize that some benefit may be maintained at reduced doses, though 800 mg daily is optimal 2
• If a patient achieves maximal benefit and wishes to discontinue, counsel that ~50% will progress within 2 years, but retreatment is effective 8